Suppr超能文献

草药(植物治疗剂)的功效、安全性、质量控制、市场营销及监管指南。

Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents).

作者信息

Calixto J B

机构信息

Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis, SC, Brasil.

出版信息

Braz J Med Biol Res. 2000 Feb;33(2):179-89. doi: 10.1590/s0100-879x2000000200004.

Abstract

This review highlights the current advances in knowledge about the safety, efficacy, quality control, marketing and regulatory aspects of botanical medicines. Phytotherapeutic agents are standardized herbal preparations consisting of complex mixtures of one or more plants which contain as active ingredients plant parts or plant material in the crude or processed state. A marked growth in the worldwide phytotherapeutic market has occurred over the last 15 years. For the European and USA markets alone, this will reach about $7 billion and $5 billion per annum, respectively, in 1999, and has thus attracted the interest of most large pharmaceutical companies. Insufficient data exist for most plants to guarantee their quality, efficacy and safety. The idea that herbal drugs are safe and free from side effects is false. Plants contain hundreds of constituents and some of them are very toxic, such as the most cytotoxic anti-cancer plant-derived drugs, digitalis and the pyrrolizidine alkaloids, etc. However, the adverse effects of phytotherapeutic agents are less frequent compared with synthetic drugs, but well-controlled clinical trials have now confirmed that such effects really exist. Several regulatory models for herbal medicines are currently available including prescription drugs, over-the-counter substances, traditional medicines and dietary supplements. Harmonization and improvement in the processes of regulation is needed, and the general tendency is to perpetuate the German Commission E experience, which combines scientific studies and traditional knowledge (monographs). Finally, the trend in the domestication, production and biotechnological studies and genetic improvement of medicinal plants, instead of the use of plants harvested in the wild, will offer great advantages, since it will be possible to obtain uniform and high quality raw materials which are fundamental to the efficacy and safety of herbal drugs.

摘要

本综述重点介绍了植物药在安全性、有效性、质量控制、市场营销和监管方面的最新知识进展。植物治疗剂是标准化的草药制剂,由一种或多种植物的复杂混合物组成,其活性成分包括粗制或加工状态的植物部位或植物材料。在过去15年中,全球植物治疗市场显著增长。仅就欧洲和美国市场而言,1999年其规模将分别达到约70亿美元和50亿美元,因此吸引了大多数大型制药公司的关注。对于大多数植物来说,现有的数据不足以保证其质量、有效性和安全性。认为草药安全且无副作用的观点是错误的。植物含有数百种成分,其中一些毒性很强,例如最具细胞毒性的抗癌植物衍生药物、洋地黄和吡咯里西啶生物碱等。然而,与合成药物相比,植物治疗剂的不良反应发生频率较低,但严格对照的临床试验现已证实这些不良反应确实存在。目前有几种针对草药的监管模式,包括处方药、非处方药、传统药物和膳食补充剂。需要对监管流程进行协调和改进,总体趋势是延续德国委员会E的经验,即将科学研究与传统知识(专论)相结合。最后,药用植物的驯化、生产、生物技术研究和基因改良趋势,而非使用野生采集的植物,将带来巨大优势,因为这样有可能获得对草药的有效性和安全性至关重要的均匀且高质量的原材料。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验